Cell Reprogramming Market Size (2024 - 2029)

Cell Reprogramming Market Analysis

The Cell Reprogramming Market size is estimated at USD 367.44 million in 2024, and is expected to reach USD 557.15 million by 2029, growing at a CAGR of 8.70% during the forecast period (2024-2029).

The rapid rise in genetic disorders globally has strongly boosted the demand for research on cell reprogramming. Data from different regulatory bodies indicate the rising number of genetic disorders globally. According to April 2024 data from the European Commission’s EUROCAT, genetic anomalies were witnessed in 20.26 cases per 10,000 births in 2022, compared to 19.6 cases per 10,000 births in 2017 in Europe. Similarly, as per data from the Australian Institute of Health and Welfare (AIHW), 4,500 (or 1.7%) of Australian babies are born with congenital disabilities each year. The University of Michigan estimates that by 2040, amyotrophic lateral sclerosis (ALS) incidence will increase worldwide by 70%. With the rising population, the frequency of such defects is also rising, leading to the growing demand for research on cell reprogramming to treat human genetic and degenerative diseases such as Parkinson's disease or ALS. This is positively impacting market growth.

The increasing prevalence of chronic diseases, coupled with an aging population and increased technological advancement in the biotechnology field, is driving the growth of the cell reprogramming market. As populations age, there is a natural increase in the prevalence of chronic diseases, including cardiovascular and neurodegenerative disorders. Moreover, the aging process is intricately linked to cellular senescence, where cells experience irreversible growth arrest. For instance, in January 2024, researchers from New York’s Cold Spring Harbor Laboratory published a paper in the journal Nature Aging, which stated that the human body’s T cells can be reprogrammed to fight aging. The T cells can be used to fend off cells that increase as a person ages and cause inflammation, rendering the aging immune system less effective over time. Similarly, in January 2023, Rejuvenate Bio announced its preclinical research evaluating cellular reprogramming for age reversal, published in the preprint server bioRxiv. Such research on the applications of cell reprogramming is a primary driver of the market.

The cell reprogramming market has immense growth opportunities due to increasing strategic initiatives such as collaboration, launches, and other activities. For instance, in February 2024, Ginkgo Bioworks announced bit.bio as an inaugural partner of the Ginkgo Technology Network, an ecosystem of cutting-edge technology providers who will collaborate with Ginkgo to provide new, integrated R&D programs. Similarly, in May 2023, Mekonos announced its partnership with bit.bio for precision cell reprogramming technology to increase the development of human cells for research, next-generation cell therapies, and drug discovery. Such partnerships promote the application of cell reprogramming, driving market growth.

Technological advancements have substantially improved the efficiency and safety of inducing pluripotency in cells. Novel reprogramming factors and precise delivery methods contribute to increased efficacy, a critical factor for the scalability and practical implementation of cell reprogramming in diverse therapeutic contexts. These technologies enable precise and targeted genome modification, facilitating the development of disease-specific cellular models for research and drug discovery. For instance, in October 2023, Tenaya Therapeutics published preclinical data in circulation, highlighting the clinical potential of cell reprogramming for cardiac regeneration.

Market growth is also influenced by advancements in automation and robotics in cell manufacturing. Automated systems streamline the production of reprogrammed cells, ensuring consistency, scalability, and compliance with regulatory standards. For instance, in January 2023, Automata announced its partnership with bit.bio, to automate a vital aspect of the manufacturing process of iPSC (induced pluripotent stem cell)-derived human cell products.

Thus, the increasing prevalence of chronic diseases, coupled with an aging population and increasing technological advancement, is driving the growth of the cell reprogramming market.

Cell Reprogramming Industry Segmentation

As per the scope of the report, cell reprogramming is a process in which the identity and characteristics of differentiated cells are altered, typically by inducing the expression of specific genes or manipulating cellular factors. Cell reprogramming aims to convert a specialized cell, often somatic or differentiated, into another cell type.

The cell reprogramming market is segmented into technology, application, end user, and geography. The market is segmented by technology into Sendai virus reprogramming, episomal reprogramming, mRNA reprogramming, and other technology types. The market is segmented by application into research and therapeutics. By end user, the market is segmented into research & academic institutes and biotechnology & pharmaceutical companies. By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. The report also offers the market sizes and forecasts for 13 countries across the region. For each segment, the market sizing and forecasts were made on the basis of value (USD).